Search

Your search keyword '"Joseph B. Quinn"' showing total 3 results
Start Over Author "Joseph B. Quinn" Journal the journal of infectious diseases
3 results on '"Joseph B. Quinn"'

1. Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects

Author

Robert G. Gish, Audrey L. Shaw, Herve Mommeja-Marin, Charles Wakeford, Gary Maartens, Michael M. Lederman, Franck Rousseau, John Bartlett, Ian Sanne, Joseph B. Quinn, and John Hinkle

Subjects
Adult, Male, medicine.medical_specialty, Efavirenz, Nevirapine, Anti-HIV Agents, HIV Infections, Emtricitabine, Gastroenterology, chemistry.chemical_compound, Acquired immunodeficiency syndrome (AIDS), Risk Factors, Internal medicine, medicine, Humans, Immunology and Allergy, Aspartate Aminotransferases, Sida, biology, business.industry, Stavudine, Lamivudine, Alanine Transaminase, medicine.disease, biology.organism_classification, Treatment Outcome, Infectious Diseases, Liver, chemistry, Immunology, HIV-1, Regression Analysis, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, Female, business, Viral load, medicine.drug
Abstract

Human immunodeficiency virus (HIV)-infected South African patients (n=468) received blinded lamivudine or emtricitabine, stavudine, and either nevirapine or efavirenz (based on screening viral load). Baseline characteristics were analyzed in univariate and multivariate regression, to identify risk factors for hepatotoxicity (grade 3 or greater increase in serum aminotransferase levels). The occurrence of early hepatotoxicity was 17% in the nevirapine group and 0% in the efavirenz group and was balanced between the lamivudine and emtricitabine arms. Two subjects died of hepatic failure. Independent risk factors were body-mass index (BMI)18.5, female sex, serum albumin level35 g/L, mean corpuscular volume85 fL, plasma HIV-1 RNA load20,000 copies/mL, aspartate aminotransferase level75 IU/L, and lactate dehydrogenase level164 IU/L. The use of nevirapine in female patients with a low BMI should be discouraged.

Published
2005
Full Text
View/download PDF

2. Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected Patients

Author

Franck S, Rousseau, Charles, Wakeford, Herve, Mommeja-Marin, Ian, Sanne, Cary, Moxham, Jeanette, Harris, Laura, Hulett, Laurene H, Wang, Joseph B, Quinn, and David W, Barry

Subjects
Adult, Adolescent, Anti-HIV Agents, HIV Infections, Pharmacology, Emtricitabine, Deoxycytidine, Virus, law.invention, Randomized controlled trial, law, Abacavir, medicine, Humans, Immunology and Allergy, Prospective Studies, Prospective cohort study, Sida, Aged, Dose-Response Relationship, Drug, biology, business.industry, Lamivudine, Middle Aged, biology.organism_classification, Dose–response relationship, Infectious Diseases, business, medicine.drug
Abstract

We conducted a randomized, open-label, 10-day study that compared the antiretroviral activity of emtricitabine (FTC) 25, 100, and 200 mg once daily and lamivudine (3TC) 150 mg 2 times/day in 82 human immunodeficiency virus (HIV)-infected patients with virus loads >5000 and

Published
2003
Full Text
View/download PDF

3. A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection

Author

K W Bockman, Judy Johnson, W J Alexander, Ralph DeMasi, P S Berry, A Stein, John Bartlett, Joseph B. Quinn, and S Graham

Subjects
Adult, Male, medicine.medical_specialty, CD8 Antigens, Placebo-controlled study, HIV Core Protein p24, HIV Infections, Placebo, Ranitidine, law.invention, Plasma, Randomized controlled trial, Acquired immunodeficiency syndrome (AIDS), Double-Blind Method, law, Internal medicine, Immunology and Allergy, Medicine, Humans, Sida, biology, business.industry, HIV, biology.organism_classification, medicine.disease, CD56 Antigen, CD4 Lymphocyte Count, Clinical trial, Infectious Diseases, Histamine H2 Antagonists, Lentivirus, Immunology, RNA, Viral, Female, business, beta 2-Microglobulin, medicine.drug
Abstract

Previous uncontrolled reports have suggested that H2-antagonists may possess immunomodulatory activity in human immunodeficiency virus (HIV)-infected patients. Such trials reported improvements in HIV-related symptoms, increased absolute CD4 cell numbers, and improvements in other measures of host immunity. The present trial was a randomized, placebo-controlled, double-blind trial of ranitidine 300 mg (orally twice daily) in subjects with early HIV infection (absolute CD4 cells, 400-700/mm3). Eighty-one subjects entered the trial and 73 completed 16 weeks on study medications. There were no significant differences in the time-weighted average change from baseline between the 2 treatment groups in absolute CD4 cell number, plasma HIV RNA level, or most other surrogate markers of HIV infection. Serum beta2-microglobulin levels were significantly lower in placebo than ranitidine recipients. Ranitidine should not be recommended for the treatment of HIV-infected patients unless it is used for established indications.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results